# Evaluating Genes in Sputum to Measure Drug Response in COPD

> **NCT00233051** · NA · TERMINATED · sponsor: **National Jewish Health** · enrollment: 20 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)
- Emphysema
- Chronic Bronchitis

## Interventions

- **DRUG:** Salmeterol or Salmeterol/Fluticasone

## Key facts

- **NCT ID:** NCT00233051
- **Lead sponsor:** National Jewish Health
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-04
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00233051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00233051, "Evaluating Genes in Sputum to Measure Drug Response in COPD". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00233051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*